CVS Caremark Reverses Course: Zepbound Reinstated, New Oral GLP-1 Added to Commercial Formularies
In a major shift, CVS Caremark, the nation’s largest pharmacy benefit manager (PBM) is reversing its controversial decision to cut coverage for one of the country’s most prescribed obesity medications.
Starting October 1, Zepbound will return to CVS Caremark’s standard commercial formularies as a preferred option. Additionally, beginning June 1, the PBM will add Foundayo, Eli Lilly’s newly approved oral GLP-1 pill, to its covered list. Both updates apply to employer-sponsored plans that opt to include weight-management benefits.
The decision concludes more than a year of intense pushback. CVS Caremark’s initial removal of Zepbound forced thousands of patients to either pay steep out-of-pocket costs or switch treatments entirely.
The exclusion triggered a class-action lawsuit in September. As recently as May 15, 2026, plaintiffs argued that dropping the drug without adequate notice violated continuity-of-care provisions. The lawsuit remains active despite the policy reversal.
With this move, CVS Caremark joins its major competitors, Express Scripts and Optum Rx, which already covered Zepbound. All three dominant PBMs are now aligned on Lilly’s flagship injectable.
Under the new structure, GLP-1 weight-loss injectables from both Eli Lilly and Novo Nordisk will hold co-preferred status. This shifts the dynamic from a restricted environment that steered patients toward a single manufacturer to one that offers genuine clinical choice.
CVS Caremark’s standard formulary impacts roughly 25 to 30 million people. However, final coverage decisions still rest with individual employers and plan sponsors.
Despite the expanded choice, CVS Health projects that the restructured formulary will actually drive down costs, generating 10% to 15% savings across the weight-management category.
The introduction of Foundayo to the formulary marks a notable evolution in obesity treatment. Approved by the FDA on April 1, 2026, Foundayo (orforglipron) is a once-daily small-molecule GLP-1 receptor agonist indicated for adults with obesity or weight-related health conditions.
Unlike existing peptide-based oral GLP-1s, Foundayo has no dietary restrictions regarding food, water, or timing, a factor expected to improve long-term patient adherence.
Clinical trials demonstrated an average weight loss of approximately 27 pounds over 72 weeks at the highest evaluated doses.
While formulary inclusion improves access, affordability remains a significant hurdle for patients whose employers opt out of weight-loss coverage.
| Medication Type | Out-of-Pocket Cost (Per Month) | Effective Date |
| Oral GLP-1 (Foundayo) | Starts at $149 | June 1 |
| Injectable GLP-1s (Zepbound/Wegovy) | $299 – $449 (dose dependent) | October 1 (Zepbound) |
| Medicare (Zepbound/Wegovy) | $50 | July 1 |
Note: The $50 Medicare copay follows recent confirmation from the Trump administration to expand coverage for Medicare patients.
CVS Caremark’s policy reversal arrives amid tightening regulatory scrutiny on compounded GLP-1 alternatives, reinforcing the market position of FDA-approved, branded therapies. For millions of patients who lost access to Zepbound last year, the October 1 reinstatement represents a long-awaited correction in commercial health benefit design.
